Myriad Genetics’ first quarter results were met with a significant negative market reaction, reflecting investor concerns ...

MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near-term outlook.

Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2025 Earnings Call Transcript May 6, 2025 Myriad Genetics, Inc. beats earnings expectations. Reported EPS is $-0.03, expectations were $-0.05. Operator ...

Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 36% in the afternoon session after the company reported mixed first quarter 2025 results: it lowered its full-year revenue, EPS ...

MYGN has been the topic of several other reports. Bank of America dropped their price target on Myriad Genetics from $13.00 to $11.00 and set an “underperform” rating ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its target price lowered by Scotiabank from $24.00 to $20.00 in a note issued to investors on Tuesday,Benzinga reports.

Myriad Genetics earned $4 million from GeneSight testing via UnitedHealthcare in 2024. Myriad reaffirms 2025 EPS guidance of $0.07-$0.11 vs. consensus of $0.06. See how Matt Maley is positioning ...

SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc ...

SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic tumor testing and precision medicine, and INTERLINK Care Management, Inc ...

Myriad Genetics, Inc. announced a study indicating that the use of its online screening tool, MyGeneHistory®, alongside a virtual education program, significantly increased the completion rates ...